The Lancet Presented with Pilot Study Results for people with ms.
- Letters, Correspondences
42 Bedford Square London WC1B SSL United Kingdom
TEL +44(0)171 4364981 FAX +44 (0)171 436 7570
JB/HEG Please quote ref:
17 September 1997
Mr Andrew Fletcher
The Multiple Sclerosis Resource Centre
4a Chapel Hill
ESSEX CM24 SAG
Dear Mr Fletcher,
I am pleased to see that some of the patients treated improved.
For our purposes, however, this account cannot be accepted as proof of efficacy. Testing new treatments in MS is a very difficult business because of the day-to-day variability of the disease.
With best wishes. Yours sincerely,
John Bignall MB Senior Editor
U.S. Agent for The Lancet, 655 Avenue of the Americas, New York, NY 10010
The Lancet Limited, 42 Bedford Square, London WC1B 3SL, U.K. Registered in England. Company number 1016593 England.